MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Invesco Pharmaceuticals ETF (NY:PJP)

126.60 +0.24 (+0.19%)
Delayed Quote Updated: 10:26 AM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Invesco Pharmaceuticals ETF

< Previous 1 2 Next >
News headline image
Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy? ↗
Here's how pharmaceutical stocks compare to biotech in terms of risk, rewards, and costs. 
Via The Motley Fool
Topics ETFs
News headline image
Big Pharma vs. Breakthrough Biotech: Which ETF Has More Upside for Investors? ↗
Both ETFs offer investors a way to profit from advances in medicine, but a closer look reveals a clear winner. 
Via The Motley Fool
Topics ETFs
News headline image
Which Pharmaceuticals ETF Is the Better Buy: iShares’ IHE or Invesco’s PJP? ↗
Pharmaceutical stocks have been one of the best places to invest over the past year. Choosing between these two funds is really a question about how you want to own what comes next. 
Via The Motley Fool
Topics ETFs
News headline image
Better Invesco Healthcare ETF: PJP Targeting Pharmaceuticals vs. RSPH's Broader Sector Lens ↗
PJP's one-year return beats RSPH's, but RSPH offers broader diversification across 61 healthcare holdings at a lower expense ratio. 
Via The Motley Fool
Topics ETFs
News headline image
Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP ↗
VanEck offers lower costs and double the dividend yield, while Invesco delivered stronger 1-year returns with more balanced holdings. 
Via The Motley Fool
Topics ETFs
News headline image
XLV vs. PJP: How Broad Healthcare Diversification Stacks Up to Pharma Stocks ↗
XLV's broader diversification and lower fees appeal to cost-conscious investors, while PJP's concentrated pharma bet has outperformed over the past year. 
Via The Motley Fool
Topics ETFs
News headline image
Invesco Pharmaceuticals vs iShares Healthcare: Which Healthcare ETF Brings Better Profits ↗
Invesco's concentrated 30-stock pharma fund delivered 43.1% returns last year, but iShares' broader 100-holding portfolio costs less and offers wider sector exposure. 
Via The Motley Fool
Topics ETFs
News headline image
Which Healthcare ETF Offers the Better Growth Outlook: VanEck Biotech or Invesco Pharmaceuticals? ↗
VanEck focuses on a clutch of biotech leaders with lower fees; Invesco tracks a select group of pharma companies with higher dividend yield and stronger five-year returns. 
Via The Motley Fool
Topics ETFs
News headline image
FHLC vs. PJP: Which Healthcare ETF Is the Better Buy for Investors? ↗
Here's how Invesco's concentrated pharma play compares to Fidelity's diversified approach to healthcare stocks. 
Via The Motley Fool
Topics ETFs
News headline image
Invesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up? ↗
One offers concentrated exposure to 29 pharma giants with lower volatility, while the other provides broader diversification across 251 biotech companies at a cheaper cost. 
Via The Motley Fool
Topics ETFs
News headline image
XPH vs PJP: Which Pharma ETF Offers Better Value ↗
State Street's lower costs appeal to buy-and-hold investors, while Invesco's concentrated portfolio and lower volatility suit risk-averse income seekers. 
Via The Motley Fool
Topics ETFs
News headline image
As Healthcare Rallies Is the Vanguard Health Care ETF of the Invesco Pharmaceuticals ETF the Better Fund for 2026? ↗
PJP surged 45% in one year, but VHT's lower costs and higher dividend yield appeal to long-term income investors seeking broad sector exposure. 
Via The Motley Fool
Topics ETFs
News headline image
Will the Invesco Pharma ETF or iShares Global Healthcare Fund Be the Better Health Care Fund in 2026? ↗
IXJ offers broader diversification with 110 holdings and a lower 0.40% expense ratio, while PJP's concentrated U.S. pharma strategy delivered a 44.90% one-year return. 
Via The Motley Fool
Topics ETFs
News headline image
PJP vs. IYH: Which Healthcare ETF Is the Better Buy? ↗
PJP delivered a higher return over the past year -- but IYH charges lower fees and pays a higher dividend yield. 
Via The Motley Fool
Topics ETFs
News headline image
Invesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026? ↗
PJP delivers lower volatility and higher income with concentrated pharma exposure, while XBI offers broader biotech growth at lower cost. 
Via The Motley Fool
Topics ETFs
News headline image
Invesco Pharmaceuticals ETF or First Trust Biotech Fund: Which Drug Maker-Focused Fund Should You Buy in 2026? ↗
PJP delivered stronger 5-year returns with lower volatility, while FBT offers broader biotech exposure at a slightly cheaper cost. 
Via The Motley Fool
Topics ETFs
News headline image
IHE vs. PJP: Which Pharmaceutical ETF Is the Better Buy for Investors? ↗
Compare the portfolio concentration, risk profiles, and long-term growth of these two pharma ETFs. 
Via The Motley Fool
Topics ETFs Intellectual Property
News headline image
Which Pharmaceutical ETF Is Better, VanEck's PPH or Invesco's PJP? ↗
Compare portfolio concentration, risk profiles, and long-term growth as these two pharma ETFs take different approaches to capturing sector opportunity. 
Via The Motley Fool
Topics ETFs
News headline image
State Street Health Care ETF Tops Invesco Pharma on Cost and Size ↗
Compare sector breadth, yield, and recent performance as these two healthcare ETFs take different approaches to growth and income. 
Via The Motley Fool
Topics ETFs
News headline image
Invesco's RSPH vs. PJP: Which Health Care ETF Is the Better Fund For The GLP-1 Revolution? ↗
Compare portfolio strategies, cost structures, and risk profiles as two Invesco healthcare ETFs take different paths to sector exposure. 
Via The Motley Fool
Topics ETFs
News headline image
Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech ↗
Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns. 
Via The Motley Fool
Topics ETFs
News headline image
Why Did CANF Stock Soar 40% In Pre-Market Today? ↗
The company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint. 
Via Stocktwits
News headline image
Merck Is Reportedly Splitting Its Pharma Division As Keytruda Patent Nears 2028 Expiry ↗
According to a Wall Street Journal report, the drugmaker said it will reorganize its human health segment into two separate units in an effort to better position its portfolio for the years ahead. 
Via Stocktwits
Topics Intellectual Property
News headline image
FDA Commissioner Raises Concerns About US Pharma Lagging Behind China In Drug Development ↗
Marty Makary, in an interview with CNBC, further called for reforms that could streamline the process for starting trials on new treatments. 
Via Stocktwits
Topics ETFs Government
News headline image
Why Did OCUL Stock Jump 13% In Pre-Market Today? ↗
French pharmaceutical giant Sanofi is preparing an offer to acquire the American biopharmaceutical firm, according to a report by French publication La Lettre. 
Via Stocktwits
News headline image
US-UK Near Landmark Zero-Tariffs Pharma Deal, Announcement Expected Soon: Report ↗
The report states that the agreement between the U.S. and the U.K. is expected to be announced in the coming days. 
Via Stocktwits
Topics World Trade
News headline image
Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' ↗
Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready to "disintermediate them." 
Via Benzinga
News headline image
Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms ↗
President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers. 
Via Benzinga
Topics Government World Trade
News headline image
Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing ↗
Mark Cuban explains how PBMs & wholesalers force pharmacies into exclusive deals, creating a 'stranglehold' on prescription drug prices. 
Via Benzinga
News headline image
Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More' ↗
Mark Cuban challenges the idea that high drug prices are necessary for R&D, PBMs take away from profits, leaving less for innovation. 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story